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Leishmania donovani promastigote membrane antigens (LAg) encapsulated in positively charged liposomes
have been found to induce very significant levels of protection against experimental visceral leishmaniasis. The
protectively immunized animals exhibited profound delayed-type hypersensitivity and antibody responses. The
extent of protection induced by the same antigens, however, varied depending on the charge of the vesicles, with
maximum induction by positively charged liposomes, followed by neutral liposomes and last negatively charged
liposomes. Characterization of LAg and LAg entrapped in liposomes of different charges by Western blot
analysis revealed the immunodominance of gp63 in all three vaccine preparations. The strong reactivity of
antigens in a restricted antigen profile that included, in addition to gp63, 72-, 52-, 48-, 45-, 39-, and 20-kDa
components in neutral and positively charged liposomes contrasted with the reactivity of a greater number of
LAg components in negatively charged liposomes. Resistance to visceral leishmaniasis appears to depend on
the immunity induced by gp63 and a few select antigens in association with the right liposomes. A striking
similarity between the immunogenic profile of partially purified soluble antigens and that of LAg in neutral and
positively charged liposomes suggests the potentiality of these antigens in future vaccine studies of L. donovani.
Leishmania species are dimorphic obligate intracellular
protozoa that cause a spectrum of diseases ranging from
cutaneous and mucocutaneous to visceral leishmaniasis affect-
ing millions of people worldwide. The cutaneous form of leish-
maniasis is generally a mild disease in humans, giving rise to
self-curing localized lesions, and has been extensively studied
in human and mouse model systems (9, 22, 41). This disease
can be caused by Leishmania major, Leishmania tropica, Leish-
mania aethiopica, and members of the Leishmania braziliensis
and Leishmania mexicana complexes. Visceral leishmaniasis is
caused by protozoa belonging to the Leishmania donovani
complex, including L. donovani and Leishmania chagasi. The
parasites multiply in the macrophages of the liver, spleen, bone
marrow, and lymph nodes, and the outcome is a potentially
fatal disease, a threat that is exacerbated by the present pan-
demic of AIDS (38, 50).
Research on the immunopathology of parasitic infections
has led to the understanding of several aspects of regulation in
the immune system. It is a consensus now that the immune
cellular response plays a central role in cutaneous leishmani-
asis. A differential activation of a Th1 CD4 lymphocyte subset
in resistant strains of inbred mice and of the Th2 subset in
susceptible strains is well documented for infections with L.
major (20, 21, 45, 46). In this model, the production of Th1-
type cytokines (interleukin-2 [IL-2] and gamma interferon)
and that of Th2-type cytokines (IL-4, IL-5, and IL-10) are
mutually exclusive. In contrast, there have been reports of the
existence of both Th1- and Th2-type responses, together with
antibodies, in murine and human visceral leishmaniasis, with a
dominance of Th1 with protective immunity (7, 14, 28–30, 40)
The development of vaccines is the essential aim of studies
on leishmaniasis. Extensive investigations in this field include
human vaccine trials with killed promastigotes and immuniza-
tion of mice with attenuated, killed, and crude parasite frac-
tions, as well as purified and recombinant antigens and their
DNA (11, 17, 31, 34, 53–55, 59). While there is still no effective
form of immunoprophylaxis against this disease, the impressive
recent advances in this area may soon result in the develop-
ment of a safe and effective vaccine. The protocols used suc-
cessfully with L. major and L. mexicana infection, however,
have been reported to be unsuccessful against murine visceral
leishmaniasis (24, 29, 39). The problems in achieving immuni-
zation may be why there are few studies of vaccines against L.
donovani (23, 44). Recently, we showed that membrane anti-
gens of L. donovani promastigotes (LAg), when entrapped in
liposomes (LAg in liposomes), could induce very significant
levels of protection against infection in both hamsters and
BALB/c mice (3). The extent of protection induced by these
antigens in mice, however, varied depending on the charge of
liposomes introduced as adjuvants such that positively charged
liposomes induced maximum protection (87%) (3), followed
by neutral (73%) (6) and negatively charged liposomes
(59.4%) (5). Identification of the key components of the com-
plex antigen mixture (LAg) incorporated in the liposome prep-
arations and determining their involvement in conferring
protective immunity are essential for the design of future sub-
unit-based vaccines against kala-azar. For this purpose, immu-
noblots of LAg and LAg in liposomes probed with infected
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sera and with sera from immunized BALB/c mice before and
after infection were analyzed. Results show that, in addition to
gp63, the major promastigote surface glycoprotein, 72-, 52-,
48-, 45-, 39-, and 20-kDa components of LAg are potent anti-
genic targets for the development of vaccine against L. dono-
vani.
MATERIALS AND METHODS
Parasites and culture conditions. Promastigotes of L. donovani, strain AG83,
were grown at 22°C in medium 199 (pH 7.4) supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin G sodium,
and 100 g of streptomycin sulfate per ml and subcultured in the same medium
at an average density of 2  106 cells/ml (6).
Preparation of Leishmania antigens. LAg were prepared from L. donovani
promastigotes as described earlier (3). Briefly, stationary-phase promastigotes,
harvested after the third or fourth passage, were washed four times in cold 20
mM phosphate-buffered saline (PBS), pH 7.2, and resuspended at a concentra-
tion of 1.0 g of cell pellet in 50 ml of cold 5 mM Tris-HCl buffer, pH 7.6. The
suspension was vortexed and centrifuged at 2,310 g for 10 min. The crude ghost
membrane pellet thus obtained was resuspended in the same Tris buffer and
sonicated in an ultrasonicator. The suspension was centrifuged at 5,190  g for
30 min, and the supernatant containing the leishmanial antigens was harvested
and stored at 70°C until use. The amount of protein obtained from a 1.0-g cell
pellet, as assayed by the method of Lowry et al. (35), was approximately 16 mg.
Soluble leishmanial antigens (SLA) were also extracted from L. donovani
promastigote membranes. The washed parasites were suspended in cold 5 mM
Tris-HCl buffer (pH 7.6) containing 5 g of leupeptin/ml, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, and 1 mM iodoacetamide (lysis buffer) and were
vortexed and centrifuged as described for LAg. The membrane pellet was resus-
pended in 10 ml of lysis buffer and sonicated as described above. The suspension
thus obtained was solubilized with 1% (wt/vol) octyl--D-glucopyranoside in the
lysis buffer, with overnight incubation at 4°C, and was finally ultracentrifuged for
1 h at 100,000  g. The supernatant containing SLA was then dialyzed against 1
mM Tris-HCl buffer (pH 7.6) and stored at 70°C until use. The amount of
protein obtained from a 1.0-g cell pellet was approximately 2 mg.
The 63-kDa membrane glycoprotein, gp63, was purified by monoclonal affinity
binding from Nonidet P-40 extracts of Leishmania amazonensis promastigotes
and was a kind gift from K. P. Chang.
Electroelution of gp63 from SDS-PAGE gels. The SLA from L. donovani
promastigotes was subjected to sodium dodecyl sulfate–10% polyacrylamide gel
electrophoresis (SDS–10% PAGE), and the protein with a molecular mass of 63
kDa (gp63) was localized in gels, stained with Coomassie blue, and eluted by
electrophoresis in running buffer (0.025 M Tris, 0.192 M glycine, 1% SDS) at 10
mA for 5 h. After elution, the protein was dialyzed, lyophilized, resuspended in
PBS, and filtered through 0.22-m-pore-size membranes for further utilization in
lymphocyte cultures (8). The protein was quantified by Lowry’s method (35).
Entrapment of leishmanial antigens in liposomes. Neutral and positively
charged liposomes were prepared with egg lecithin and cholesterol (7:2 molar
ratio) or with egg lecithin, cholesterol, and stearylamine (7:2:2 molar ratio),
respectively, as reported earlier (3, 6). Negatively charged liposomes were pre-
pared with egg lecithin, cholesterol, and phosphatidic acid at a molar ratio of
7:2:2 (5). For encapsulation of the antigens in the vesicles the lipid film was
dispersed in PBS containing 2 mg of LAg/ml and sonicated for 30 s in an
ultrasonicator. Liposomes with entrapped antigen were separated from the ex-
cess free antigen by three successive washing in PBS with ultracentrifugation
(105,000  g, 60 min, 4°C). The amounts of LAg associated per milligram of egg
lecithin were 35, 25, and 15 g for positively charged, neutral, and negatively
charged liposomes, respectively. Similarly, electroeluted gp63 was entrapped in
the positively charged vesicles. The lipid film was dispersed in PBS containing 1
mg of gp63/ml, and 40 g of protein was associated with 1 mg of egg lecithin.
Immunization and challenge infection. BALB/c mice were immunized by
three intraperitoneal injections of 20 g of LAg or 10 g of gp63, purified by
electroelution and free in PBS or entrapped in liposomes, at 2-week intervals.
Animals receiving only PBS or empty liposomes served as controls. Ten days
after the last immunization, the immunized and control animals were challenged
intravenously with 2.5  107 freshly transformed L. donovani promastigotes (6).
Serum samples collected from each mouse before challenge infection and at 4
months postinfection were stored frozen at 20°C.
DTH. Delayed-type hypersensitivity (DTH), was determined as an index of
cell-mediated immunity. The response was evaluated by measuring the difference
between the footpad swelling at 24 h following intradermal inoculation of the test
footpad with 50 l of electroeluted gp63 (800 g/ml) and the swelling of the
control (PBS-injected) footpad (3).
Cell proliferation assay. The lymphocyte cultures were obtained from spleens
of immunized BALB/c mice. The cells were isolated and counted, and, after
evaluation of cell viability by trypan blue exclusion, 2  105 cells per well were
cultured in RPMI 1640 containing 20 mM NaHCO3, 10 mM HEPES, 100 U of
penicillin per ml, 100 g of streptomycin per ml, 2 mM L-glutamine, and 10%
fetal calf serum (complete medium [CM]), with 50 M -mercaptoethanol
added.
The cells were cultured in triplicate in a final volume of 200 l/well with eluted
antigen (0.7 g/well) at optimum concentrations. The cultures were incubated
for 96 h at 37°C in a humidified chamber containing 5% CO2. Cells were pulsed
with 1 Ci of [3H]thymidine ([3H]TdR; 83 Ci/mmol; Amersham International,
Amersham, England) per well 18 h before they were harvested on glass fiber
paper. ([3H]TdR uptake was measured in a -scintillation counter (LS 5000TD;
Beckman Instruments, Fullerton, Calif.).
In vitro growth of L. donovani in macrophages. Macrophages were collected by
peritoneal lavage from immunized BALB/c mice 10 days after the last injection
and cultured in CM. A total of 90% of the cell preparation was identified as
macrophages by microscopic observation, and the macrophages were routinely
found to be 98% viable by trypan blue exclusion.
Promastigotes were used to infect cultures of adherent macrophages on glass
coverslips (18 mm2; 106 macrophages/coverslip) in 0.5 ml of CM at a ratio of 10
parasites/macrophage. After 3 h of incubation, the unphagocytosed parasites
were removed by a washing with PBS. Infected macrophages were further incu-
bated in CM at 37°C for 72 h. Cells were fixed in methanol and stained with
Giemsa for determination of intracellular parasite numbers.
ELISA. Mice immunized with gp63 or gp63-positively charged liposome and
control BALB/c mice were bled 10 days after the last immunization by snipping
the tail vein, and the sera were collected. Serum IgG levels were determined by
enzyme-linked immunosorbent assay (ELISA) (3). Briefly, 96-well microtiter
plates were coated overnight at 4°C with gp63 that had been purified by elec-
troelution (15 g/ml). After being blocked with bovine serum albumin and
incubated overnight with serum samples diluted at 1:1,000, the plates were
developed by using a 1:5,000 dilution of peroxidase-conjugated goat anti-mouse
immunoglobulin G (IgG) antibody (Jackson Immunochemical Research Labo-
ratories).
Mice sera were further assayed for gp63-specific IgG subclass antibodies with
a mouse antibody isotyping kit (Sigma Immunochemicals, St. Louis, Mo.). gp63-
coated wells, incubated with mice sera as described above, were reacted over-
night at 4°C with a 1:2,500 dilution of goat anti-mouse isotype-specific antibodies,
followed with a 1:5,000 dilution of peroxidase-conjugated rabbit anti-goat IgG
(Jackson Immunochemical Research Laboratories). The plates were developed
for color reaction and analyzed by measuring the optical density at 450 nm.
Evaluation of infection. At the times mentioned in Results, the course of
infection was monitored by the microscopic examination of Giemsa-stained im-
pression smears of liver and spleen. The parasite load was expressed as Leish-
man-Donovan units and was calculated by the following formula: number of
amastigotes per 1,000 cell nuclei  organ weight (in milligrams) (57).
SDS-PAGE and Western blot analysis. Components of the L. donovani pro-
mastigote membrane were subjected to SDS-PAGE by the method of Laemmli
(32). Gels were loaded with proteins (amounts are indicated in the figure leg-
ends) of the L. donovani ghost membrane; LAg and SLA free in PBS; LAg
entrapped in liposomes of neutral, negative, and positive charge; purified gp63
provided by Chang; and gp63 purified by electroelution. Proteins, separated on
10% polyacrylamide, were silver stained (61).
For Western blot analysis, the resolved proteins were transferred onto nitro-
cellulose in 25 mM Tris-HCl–192 mM glycine–20% (vol/vol) methanol buffer at
90 V/cm for 90 min (58). Immunoblot assays were performed according to the
method described by Rolland-Burger et al. (49) with slight modifications. The
nitrocellulose strips were first saturated and then blocked overnight at room
temperature in 100 mM Tris-buffered saline (TBS), pH 7.6, containing 0.1%
Tween 20 (T-20) and washed once for 15 min with 0.05% T-20 in TBS (washing
buffer) with shaking. Incubation of the nitrocellulose strips with sera from mice
immunized with LAg in liposomes, before and after infection, was carried out at
1:500 dilution in the washing buffer for 1 h at room temperature, followed by
three washes of 20 min each. gp63, SLA, LAg, and LAg-in-liposome blots were
probed with rabbit antisera to purified gp63 at 1:200 dilution, kindly provided by
K. P. Chang. The blots were then washed and incubated with peroxidase-conju-
gated anti-mouse or anti-rabbit (Sigma Immunochemicals) IgG, at a 1:500 dilu-
tion in the washing buffer for 1 h at room temperature; this was followed by three
washes as described above. The last wash was done without T-20. Enzymatic
activity was revealed with 15 mg of 3,3-diaminobenzidine tetrahydrochloride
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(Sigma Immunochemicals) in 30 ml of TBS containing 15 l of 30% H2O2. The
efficacy of transfer of the leishmanial proteins was regularly checked and con-
firmed by concurrent gel staining with silver and nitrocellulose membrane stain-
ing with 0.1% Ponceau S in 1% acetic acid. The parts of the membrane contain-
ing molecular mass standards were marked with ink after the staining with
Ponceau S. The specificity of the immune response was assessed by immunoblot
analysis employing pooled preimmune sera and only liposome-immunized sera at
1:50 dilution and infected sera at 1:500 dilution in washing buffer.
Statistical analysis. All data comparisons were tested for significance by using
Student’s t test; P values of 0.05 were considered significant.
RESULTS
Electrophoretic analysis of the leishmanial antigens and
antigens in liposomes. LAg in association with liposomes in-
duce strong protection against virulent homologous challenge
(3, 6). These antigens were extracted from the promastigote
ghost membrane (Fig. 1, lane 1) and exhibited at least 33
distinct polypeptides (lane 2) ranging in molecular mass from
18 to 153 kDa. Entrapment of LAg in liposomes of different
charges (lanes 6 to 8) revealed different polypeptide profiles in
vesicles of negative (lane 6), neutral (lane 7), and positive (lane
8) charge. The silver stain data illustrate that preparations of
liposomes resulted in preferential entrapment of some pro-
teins. Polypeptides with molecular masses above 64 kDa,
weakly displayed in LAg as well as in the ghost membrane,
were predominantly associated with liposomes. Again, a 61- to
66-kDa band, present as a 63- to 64-kDa polypeptide in LAg
but not as the major component, stained more intensely in
neutral and positively charged vesicles than in negatively
charged liposomes. This band demonstrated a comigration
with the major polypeptide of purified gp63 provided by Chang
(lane 4). An attempt at partial purification of LAg through
detergent solubilization resulted in the extraction of approxi-
mately six polypeptides (72, 63, 43, 41, 30, and 20 kDa) and a
faint smear in the region of 45 to 52 kDa, with the major band
also comigrating with gp63 (lane 3). gp63 purified by electro-
elution stained as a single band representing a 63-kDa
polypeptide (lane 5). Amounts of empty liposomes equal to the
amounts of liposomes with LAg were subjected to SDS-PAGE.
No bands were observed (data not shown).
Immunoblot analysis of LAg and LAg in liposomes with
immunized mice sera before and after infection. The antige-
nicities of the components of LAg and LAg in liposomes were
studied by performing Western blot analysis on a series of blots
of LAg (Fig. 2, lanes 1, 3, and 5) and LAg entrapped in
positively charged (lane 2), neutral (lane 4), and negatively
charged (lane 6) liposomes. Antigenic profiles were character-
ized by a dominant 61- to 66-kDa band for LAg in positively
charged liposomes as well as for LAg and additional reactivity
with 72-, 52-, 48-, and 45-kDa polypeptides on LAg by sera
from mice immunized with LAg entrapped in positively
charged liposomes (Fig. 2, lanes 1 and 2). Identical blots of
LAg and LAg in neutral liposomes probed with sera from mice
immunized with LAg in neutral liposomes show recognition of
a 62- to 64-kDa band, followed by 45- and 39-kDa bands, on
blots of LAg in liposomes (lane 4) and a dominant 45-kDa
band, followed by 62- to 64-, 36-, and 18-kDa bands, on LAg
blots (lane 3). Sera from mice immunized with LAg in nega-
tively charged liposomes recognized a number of bands on
blots of both LAg (lane 5) and LAg in liposomes (lane 6). In
addition to the 62- to 64- and 45-kDa bands, which appeared
on both blots, the antigenic profiles were characterized by
bands at 80, 39, and 20 kDa on the blots of LAg in liposomes
and bands at 143, 72, 70, 50, 48, and 36 kDa on LAg blots.
Figure 3 presents the antigenic profiles of similar samples of
LAg and LAg in liposomes that reacted with sera from mice
immunized with LAg entrapped in liposomes after 4 months of
infection. The antibodies with enhanced titers that were elic-
ited after infection of mice immunized with LAg in positively
charged liposomes recognized several antigens of LAg (lane
1). The same sera, however, showed reactivity mainly with the
61- to 66-kDa band followed by 72-, 52-, 48-, 45-, 28-, and
20-kDa components of LAg in liposomes (lane 2). Antigen
recognition by immunized mouse sera after 4 months of infec-
tion with LAg in neutral liposomes was, however, limited for
both LAg (lane 3) and LAg in liposomes (lane 4), demonstrat-
FIG. 1. Silver-stained SDS-PAGE gel of Leishmania antigens in
liposomes. Lanes: 1, ghost membrane (20 g); 2, LAg (20 g); 3, SLA
(4 g); 4, gp63 (Chang’s; 2 g); 5, gp63 purified by electroelution (4
g); 6 to 8, LAg entrapped in negatively charged (lane 6), neutral (lane
7), and positively charged (lane 8) liposomes (6 g). The positions of
prominent bands are shown at the right as apparent molecular masses
in kilodaltons.
FIG. 2. Immunoblot profiles of LAg in liposomes following reac-
tions with immunized mouse sera. LAg (20 g; lanes 1, 3, 5) and equal
amounts of LAg in positively charged (6 g; lane 2), neutral (lane 4),
and negatively charged (lane 6) liposomes were subjected to SDS-
PAGE and Western blotting. Sera from BALB/c mice immunized with
LAg in positively charged (lanes 1 and 2), neutral (lanes 3 and 4), and
negatively charged (lanes 5 and 6) liposomes were used at 1:500 dilu-
tion. Relative molecular masses of the prominent bands (in kilodal-
tons) are represented on the right.
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ing a reactivity predominantly for the 62- to 64-kDa band
followed by 52-, 48-, 45-, and 20-kDa moieties. Antibodies
elicited in mice immunized with LAg in negatively charged
liposomes revealed the strongest reactivity with components of
LAg and LAg in liposomes after 4 months of infection. Al-
though the 61- to 66-kDa band was still the dominant compo-
nent of LAg (lane 5), there were several additional bands as
well as smears of LAg in negatively charged liposomes (lane 6)
recognized by the antisera.
Reactivity of LAg and LAg in liposomes with infected sera is
illustrated in Fig. 4. While there was a dominant 61- to 66-kDa
band of LAg with immunized-mouse sera before and after
infection (Fig. 2 and 3), sera from unimmunized, infected mice
exhibited predominantly a 59-kDa band of LAg (Fig. 4, lane 1).
Other components recognized by the infected sera include
bands of 143, 72, 52, 48, 45, 39, 36, and 20 kDa, as well as
smears in the range of 60 to 66, 50 to 58, and 18 to 22 kDa.
Infected sera reacted with LAg in liposomes with lower inten-
sity, recognizing only 66-, 60-, 48-, and 45-kDa bands for LAg
in positively charged liposomes (lane 2); 80-, 28-, and 20-kDa
bands for LAg in neutral liposomes (lane 3); and 80-, 66-, and
36-kDa bands for LAg in negatively charged liposomes (lane
4). No bands were present on identical sets of blots probed
with normal mouse sera or sera from mice immunized with
empty liposomes (data not shown).
Western blot analysis of SLA with sera from mice immu-
nized with LAg in liposomes before and after protection. The
antigenic profile of the components of SLA in sera from mice
immunized with LAg entrapped in liposomes (Fig. 5) was char-
acterized by bands at molecular masses of 72, 48, and 45 kDa
and a predominant band of 60 to 66 kDa (lanes 1 to 3), with
additional bands of 52 kDa for positively charged liposomes
(lane 1) and 20 kDa for neutral liposomes (lane 2). The profile
of SLA in sera from mice immunized with LAg in neutral
liposomes following infection remained the same (lane 6).
However, additional bands of 41, 39, and 20 kDa for LAg in
positively charged liposomes (lane 5) and of 52, 39, and 18 kDa
for LAg in negatively charged liposomes (lane 7) in mouse sera
after 4 months of infection were observed. In the sera from
unimmunized, infected mice (lane 4) the reaction was of a
lower intensity and a doublet of 59 and 63 kDa replaced the
immunodominant 61- to 66-kDa band reactive with sera from
mice immunized with LAg in liposomes, while the rest of the
profile remained the same.
Expression of gp63. The dominant band of 61 to 66 kDa for
LAg in liposomes as well as SLA exhibited a relative mobility
very similar to that of the band for purified gp63 obtained from
Chang (Fig. 1). The specificity of gp63 in blots of LAg, LAg in
liposomes, and SLA was confirmed through reactivity with a
polyvalent rabbit antiserum raised against this purified protein
(Fig. 6). gp63 recognized by anti-gp63 (lane 6) appeared as a
doublet of 61 to 66 kDa in LAg (lane 1), LAg in liposomes
FIG. 3. Immunoblot analysis of LAg in liposomes with immunized-
mouse sera after 4 months of infection. LAg (lanes 1, 3, and 5) and
LAg in liposomes (positively charged, lane 2; neutral, lane 4; negatively
charged, lane 6) fractionated by SDS-PAGE were probed with sera
from infected mice immunized with LAg entrapped in positively
charged (lanes 1 and 2), neutral (lanes 3 and 4), and negatively charged
(lanes 5 and 6) liposomes following electrotransfer to nitrocellulose.
The amounts of proteins loaded were as described for Fig. 2. Numbers
on the right represent the prominent bands (in kilodaltons).
FIG. 4. Reactivity of LAg and LAg in liposomes with infected-
mouse sera. Blots of LAg (lane 1) and LAg in positively charged (lane
2), neutral (lane 3), and negatively charged (lane 4) liposomes were
probed with a 1:500 dilution of sera from mice infected for 4 months.
Amounts of proteins loaded were identical to those for Fig. 2. Num-
bers indicate molecular masses in kilodaltons.
FIG. 5. Western blot analysis of SLA. SLA (4 g) was separated by
SDS-PAGE, and the proteins were immunoblotted with sera from
mice after immunization with LAg entrapped in positively charged
(lanes 1 and 5), neutral (lanes 2 and 6), and negatively charged (lanes
3 and 7) liposomes before (lanes 1 to 3) and after (lanes 5 to 7)
infection. A similar blot of SLA (lane 4) was probed with sera from
unimmunized, infected mice. The positions of prominent bands are
shown at the right.
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(lanes 3 to 5), and SLA (lane 2) with almost equal intensities
and specificities. No bands were present on a similar set of
blots probed with normal rabbit serum (data not shown).
Vaccination with gp63 entrapped in liposomes. To investi-
gate the protective efficacy of gp63 in a liposomal formulation,
BALB/c mice were immunized with gp63 purified by electro-
elution, both free gp63 and gp63 entrapped in positively
charged liposomes, prior to challenge with L. donovani pro-
mastigotes. The positively charged vesicles were selected be-
cause the maximum level of protection against experimental
visceral leishmaniasis was observed with these liposomes. After
2 and 4 months of infection mice were sacrificed and parasite
loads in their livers and spleens were quantified (Fig. 7). An-
imals immunized with gp63 and gp63 entrapped in liposomes
demonstrated significantly enhanced resistance to hepatic in-
fection with L. donovani; the protection induced was 22.8 and
40%, respectively, at 2 months, and 41 and 57%, respectively,
at 4 months, compared to the resistance of mice receiving only
PBS (P  0.01) (Fig. 7A). The level of protection induced by
liposomal gp63 was higher than that with free gp63. However,
the difference was not statistically significant. Vaccination with
liposomal gp63 could also induce significant protection against
parasite growth in the spleen (46% at 2 months and 60% at 4
months; P  0.02) (Fig. 7B). In contrast, free gp63 failed to
provide protection in this organ. These results demonstrated
the partial but significant vaccine potentiality of gp63 in a
liposomal formulation.
Immunization with liposomal gp63 induced the highest level
of DTH before, as well as after, challenge infection, correlating
with the acquired resistance to infection observed in this group
(Fig. 8A). Free gp63 could also induce DTH responses after
immunization. However, after infection the levels of the re-
sponses did not differ significantly from those for the controls.
Vaccine-induced stimulation of the cell-mediated immune
response was further investigated through the capacity of
spleen cells to proliferate in response to concanavalin A and
gp63 after immunization. The in vitro responses to the mitogen
evaluated 10 days after immunization were found to be strong-
ly proliferative, with no differences between the control and
the antigen-immunized groups (data not shown). In the gp63-
specific-restimulation assays, cells from mice immunized with
liposomal gp63, but not free gp63, proliferated significantly
more than controls (P  0.05) (Fig. 8B). A slight proliferative
response, however, was also displayed by spleen cells from
control mice and mice immunized with gp63 alone when re-
stimulated in vitro. Similar lymphoproliferative responses have
been observed earlier for mice immunized with gp63 alone or
only adjuvant when stimulated in vitro with gp63 or SLA,
respectively (48, 2). Immunization with gp63, free as well as in
a liposome formulation, could also activate peritoneal macro-
phages to arrest L. donovani amastigote multiplication in vitro
(Fig. 8C). The leishmanicidal activity of macrophages from
gp63-liposome immunized mice was, however, significantly
higher (P  0.002) than that of those from free-gp63-immu-
nized mice. In addition, the percentage of infected macro-
phages for the liposomal antigen-immunized mice was lower
than that for free-antigen-immunized mice (12 versus 53%),
demonstrating the enhanced adjuvant activity of the liposomal
formulation of gp63. Immunization with gp63 in liposomes
induced a strong humoral immune response (Fig. 8D), which
was not observed in free-gp63-immunized or control animals.
Th1 and Th2 cells, implicated in differential host response to
infectious diseases, promote cellular as well as humoral im-
mune responses. Since antibody isotype profiles provide a con-
venient surrogate marker for Th1 and Th2 subsets of CD4
cells (1, 12), we further evaluated the levels of gp63-specific
IgG isotype antibodies in serum from the immunized mice
(Fig. 8E). Elicitation of significantly higher levels of IgG2a and
IgG2b than of IgG1 (P  0.01) points to a Th1-dominated
immune response (15) stimulated by gp63 entrapped in lipo-
somes.
DISCUSSION
In our attempt to design a vaccine against visceral leishman-
iasis we initiated studies with LAg in association with lipo-
somes as the adjuvant. Entrapment of these antigens in the
lipid vesicles conferred significant levels of protection against
infection in BALB/c mice. However, the extent of protection
showed marked variation for the same antigens depending on
whether liposomes were positively charged (3), neutral (6), or
negatively charged (5). The variations may be a result of dif-
ferential entrapment of the various components of LAg or an
adjuvant-induced difference in the immune responses to LAg.
Our data indicate that a few immunodominant parasite anti-
gens can elicit strong protective immune responses when used
in the context of appropriate adjuvants.
Characterization of the antigens entrapped in liposomes by
SDS-PAGE revealed preferential entrapment of a 61- to 66-
kDa promastigote antigen by all the liposome preparations. In
addition, a number of other proteins of LAg were entrapped
within the vesicles. However, all these components were not
immunogenic, and their profiles varied with the charge of the
associated vesicle. While a few polypeptides, including the
dominant 62- to 64-kDa polypeptide, demonstrated seroreac-
tivity in neutral and positively charged liposomes, a larger
number were seroreactive in association with negatively
charged vesicles, with antisera obtained through the corre-
FIG. 6. Western blot analysis of gp63 expression in liposomes con-
taining LAg. Blots of LAg (20 g; lane 1); SLA (4 g; lane 2); LAg in
positively charged (6 g; lane 3), neutral (6 g; lane 4), and negatively
charged (6 g; lane 5) liposomes; and gp63 (Chang’s; 2 g; lane 6)
were probed with a 1:200 dilution of polyclonal rabbit anti-gp63 sera
and developed with diaminobenzidine and H2O2 as described in Ma-
terials and Methods.
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sponding vaccine preparation. The reactivity of LAg and LAg
in liposomes was enhanced with sera from immunized mice
after infection. However, apart from the antigens in negatively
charged liposomes, selective seroreactivity of LAg components
was again observed for neutral and positively charged lipo-
some-associated antigens. Of the antigens recognized by anti-
sera before and after infection, the 62- to 64-kDa component
was the most seroreactive component of LAg in all three vac-
cine preparations, followed by distinctive bands at 72, 52, 48,
45, and 20 kDa, especially on blots of neutral and positively
charged LAg in liposomes. Interestingly, SLA, partially puri-
fied from LAg, also demonstrated maximum reactivity at 62 to
64 kDa, followed by strong bands at 72, 52, 48, 45, and 20 kDa,
with the sera from mice immunized with LAg in liposomes
demonstrating a profile with a striking resemblance to the
immunodominant-antigen profiles for neutral and positively
charged liposomes. In contrast, sera from unimmunized, in-
fected mice recognized different polypeptides of LAg. Reac-
tivity with the components of LAg entrapped in the different
liposomes was low and lacked the dominance of the 62- to
64-kDa antigen observed with the immunized sera.
That the immunodominant antigen among LAg and LAg in
liposomes was gp63 was confirmed through reactivity with an-
tiserum against this purified protein. Preferential entrapment
of gp63 from the crude mixture of L. major promastigotes in
liposomes was also demonstrated by Kahl et al. (27) despite the
differences in the use of the phospholipids and the vesicle
preparation. These workers identified gp63 as the principal
FIG. 7. Kinetics of protection against L. donovani in liver (A) and spleens (B) of BALB/c mice immunized with PBS, empty liposomes, gp63
in PBS, and gp63 in liposomes. After three intraperitoneal immunizations, mice were challenged intravenously with L. donovani promastigotes and
the parasite burdens at 2 and 4 months of infection were calculated as described in Materials and Methods. The mean values 	 standard errors
(error bars) for three mice per group are given.
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FIG. 8. Immune responses elicited by gp63 in positively charged liposomes in BALB/c mice. (A) gp63-specific DTH in immunized and
challenged mice expressed as the difference (in millimeters) between the thicknesses of the test (gp63-injected) and control (PBS-injected)
footpads. (B) Lymphoproliferative responses of gp63-immunized mice. The stimulation index of the liposomal gp63 group (mean counts per
minute of cells stimulated with gp63 in triplicate/mean counts per minute of medium controls) was 4.1. (C) Immunization induced activation of
mouse peritoneal macrophages to suppress intracellular amastigote proliferation 72 h after infection in vitro with L. donovani. (D and E) Serum
IgG (D) and IgG (E) subclass antibody responses in immunized mice were assayed by ELISA on gp63-coated microtiter plates incubated overnight
with a 1:1,000 dilution of sera, as described in Materials and Methods. Results are shown as the mean 	 standard errors of the means for three
individual mice. O.D., optical density.
VOL. 70, 2002 IMMUNOGENIC L. DONOVANI ANTIGENS IN LIPOSOMES 6703
 o
n
 July 23, 2014 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
protein antigen conferring protection. The identification of
defined parasite proteins and peptides that induce beneficial
immune responses may contribute to vaccine development.
gp63, the major surface glycoprotein of Leishmania, is highly
conserved across species (37), and its role in induction of
protection against murine cutaneous leishmaniasis has been
extensively investigated (25, 51, 64). The subjects of the studies
range from the use of the native protein (13, 16, 51) to the use
of recombinant gp63 (rgp63) expressed in Salmonella spp. (64)
or plasmid pCMV, which encodes gp63 (62), to the use of
T-cell epitopes within gp63 (25, 63). However, even though L.
donovani gp63 has been identified (33) and purified in its
native and recombinant forms (43, 52), its role in protection
against infection with L. donovani has not been established.
Partial heterologous protection against L. donovani infection
in mice by L. major rgp63 expressed in Salmonella was re-
ported (36). To our knowledge this is the first report of an
involvement of L. donovani gp63 in protection against the
visceral infection in mice.
Even though gp63 was the immundominant antigen of LAg
in all the three liposomes, protection conferred by these prep-
arations varied significantly. The choice of adjuvant is impor-
tant in inducing the correct immune response. In a study un-
dertaken with pure M2 and three different adjuvants, marked
variations in the protection against L. mexicana amazonensis
conferred by each preparation were observed (11). It has been
shown that cloned T cells with opposite biological effects on
murine models of cutaneous leishmaniasis utilize the same or
similar T-cell receptors (47), suggesting that a particular anti-
gen may elicit either a protective or an exacerbating immune
response against L. major. L. major antigens drive either a
Th1- or Th2-type T-cell response, depending on the local cy-
tokine environment during antigen priming (10, 26, 27, 59).
Antigens of L. donovani, however, did not induce exacerba-
tion. Investigation of the immune responses to the vaccine
preparations showed that LAg in neutral liposomes elicited a
weak but exclusively Th1-type response after immunization, as
characterized by the antibody isotype profile (4). In contrast,
the same antigens in positively and negatively charged lipo-
somes induced both Th1- and Th2-type responses. However,
while high levels of IgG2a and IgG2b (markers for the induc-
tion of a Th1-like response) were simultaneously stimulated,
along with IgG1 (Th2-like response), with positively charged
liposomes (3), these isotypes were dominated by the levels of
IgG1 stimulated by immunization with LAg in negatively
charged vesicles (5). These data indicate that, in contrast to
what was found for L. major antigens (55), a concomitant Th2
response with L. donovani antigens does not inhibit the strong
Th1 effector function. This conclusion was further substanti-
ated by our investigation of the vaccine potentiality of gp63,
purified by electroelution, in association with liposomes. En-
hanced protection induced with gp63 in a liposomal formula-
tion corresponded with stronger stimulation of cellular as well
as humoral immune responses in comparison with stimulation
by gp63 alone. Further analysis of IgG isotypes revealed in-
duction of all the isotypes, suggesting stimulation of both Th1-
and Th2-like responses by gp63 in a vaccine formulation. How-
ever, stimulation of higher levels of IgG2a and IgG2b antibod-
ies than of IgG1 antibodies indicates the stronger potentiation
of a protective Th1 response. The development of a vaccine
against L. donovani may, therefore, require that a particular
antigen be administered in the context of the right adjuvant for
potentiating a dominant Th1 response.
Although gp63 was maximally incorporated in the lipo-
somes, in contrast to the L. major antigens (27), a greater
number of other proteins of L. donovani LAg were also en-
trapped in the vesicles. However, only a few were immunore-
active with sera from protectively immunized animals and
therefore likely to be involved in immunoprotection. While the
identity of the 61- to 66-kDa band was confirmed, 72-, 52-, 48-,
45-, 39-, 36-, and 20-kDa antigens of LAg remain unidentified.
Screening for parasite antigens on the basis of reactivity with
sera from infected susceptible animals has led to the identifi-
cation of several leishmanial antigens having the ability to
confer protective immunity. Some of these well-defined anti-
gens detected through antibody reactivity include LPG (18),
gp46/M-2 (11), dp72 (24), PSA-2 (19), P4 and P8 (56), Lcr1
(61), and LACK (42, 59). Purified antigens such as L. donovani
dp72 and highly conserved polypeptides of Leishmania species
such as gp46 and LACK, of 46 and 36 kDa, respectively, may
be identified with the immunoreactive components of L. do-
novani LAg in liposomes and need further testing. In contrast
to LAg, SLA, the partially purified antigens from LAg, dem-
onstrated a restricted seroreactivity comparable to that of
polypeptides of LAg in positively charged liposomes which
exhibited maximum protective activity. Although gp63 is one of
the most immunogenic of Leishmania antigens, it is only par-
tially protective against murine visceral leishmaniasis, as ob-
served herein, and against lethal murine cutaneous leishman-
iasis, as observed elsewhere (13, 25, 51, 64). It has been
suggested that the efficacy of gp63 could be enhanced, possibly
with additional Leishmania antigens (13). Since SLA is com-
posed of most of the antigens, including gp63, immunogenic in
LAg in liposomes and since it induces better protection than
gp63 or LAg in liposomes (Rajesh et al., unpublished data), we
propose that its components, polypeptides of 72, 52, 48, 45, 41,
39, and 20 kDa, in addition to gp63, be vaccine candidates for
future studies of L. donovani antigens in liposomes.
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